Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AKST4290 in Subjects With Parkinson's Disease on Stable Dopaminergic Treatment

NCT04369430 is registered in ClinicalTrials.gov with Alkahest, Inc. as lead sponsor.

NCT NCT04369430
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04369430 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AKST4290 in Subjects With Parkinson's Disease on Stable Dopaminergic Treatment
Lead sponsor
Alkahest, Inc.
Phase
Phase 2
Overall status
Completed
Start date
January 16, 2020
Completion date
March 10, 2021
Enrollment
110 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson disease